US 12,115,216 B2
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
Kevin A. Bray, Garnerville, NY (US); Frank Delfino, Poughquag, NY (US); Matthew C. Franklin, Great Neck, NY (US); Elena S. Garnova, White Plains, NY (US); Jessica Kirshner, New York, NY (US); Douglas MacDonald, New York, NY (US); William Olson, Yorktown Heights, NY (US); and Gavin Thurston, Millerton, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Dec. 15, 2022, as Appl. No. 18/081,782.
Application 16/992,188 is a division of application No. 16/019,703, filed on Jun. 27, 2018, granted, now 10,806,780, issued on Oct. 20, 2020.
Application 18/081,782 is a continuation of application No. 16/992,188, filed on Aug. 13, 2020, granted, now 11,559,576.
Claims priority of provisional application 62/525,937, filed on Jun. 28, 2017.
Prior Publication US 2023/0270837 A1, Aug. 31, 2023
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01); C07K 16/08 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/0008 (2013.01); A61K 39/0011 (2013.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C07K 16/084 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); C07K 16/2875 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); C07K 2317/32 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
 
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR),
wherein the CAR comprises an extracellular binding domain that specifically binds to a conformational epitope of an HLA-A2 presented human papillomavirus (HPV) 16 E7 peptide (HPV16E7 peptide), a transmembrane domain, and an intracellular signaling domain,
wherein the extracellular binding domain is a human monoclonal anti-HLA-A2:HPV16E7 antibody, or antigen-binding fragment thereof, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3); and three light chain CDRs (LCDR1, LCDR2 and LCDR3),
wherein the HCDR1, HCDR2 HCDR3, LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence set having at least 90% amino acid sequence identity to the entire amino acid sequence of SEQ ID NOs: 508, 510, 512, 516, 518, and 520, respectively.